Physician profile
William W Lin
NPI 1396776209
$2,000.75
in general payments reported to CMS, 2019-2025
24 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $177 · 2023: $358 · 2024: $626 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.35 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $366.81 | 2025 | Cvac Aspiration System |
| Antares Pharma, INC. | $321.08 | 2024-2025 | Xyosted, Tlando |
| Abbvie INC. | $180.39 | 2024 | |
| Procept Biorobotics Corporation | $177.11 | 2021 | |
| Endo USA, INC. | $148.83 | 2024-2025 | Xiaflex |
| Merck Sharp & Dohme LLC | $115.23 | 2019 | |
| Teleflex LLC | $109.98 | 2023-2024 | Urolift |
| Coloplast Corp | $105.02 | 2023-2025 | Speedicath |
| Halozyme INC | $85.58 | 2023 | |
| Janssen Biotech, INC. | $56.53 | 2023-2024 | Erleada, Akeega, Balversa |
| Convatec INC. | $48.21 | 2023-2024 | |
| Astellas Pharma US INC | $48.08 | 2023-2025 | Xtandi, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $28.79 | 2023 | |
| Dendreon Pharmaceuticals LLC | $28.67 | 2025 | Provenge |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.01 | 2025 | |
| Laborie Medical Technologies Corp. | $25.57 | 2025 | |
| Accord Healthcare, INC. | $21.05 | 2024 | |
| Sun Pharmaceutical Industries INC. | $20.65 | 2023 | Yonsa |
| Olympus America INC. | $19.41 | 2023 | Itind System |
| Myriad Genetic Laboratories, INC. | $18.16 | 2024 | Myrisk |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2023 | Seglentis |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.